We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+32.61%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$439M
AUM Growth
+$21.9M
Cap. Flow
-$50M
Cap. Flow %
-11.37%
Top 10 Hldgs %
49.48%
Holding
86
New
10
Increased
12
Reduced
30
Closed
14
Avg Time Held
10.8 quarters
Top 10 Avg Time Held
6.1 quarters
Top 20 Avg Time Held
9.8 quarters

Top Buys

Rank Stock Value
1
ATRC icon
AtriCure
ATRC
+$4.87M
2
PODD icon
Insulet
PODD
+$2.97M
3
KALV icon
KalVista Pharmaceuticals
KALV
+$2.75M
4
CATX icon
Perspective Therapeutics
CATX
+$2.65M
5
LRMR icon
Larimar Therapeutics
LRMR
+$2.59M

Top Sells

Rank Stock Value
1
KRTX icon
Karuna Therapeutics, Inc. Common Stock
KRTX
+$15.2M
2
IMGN icon
Immunogen Inc
IMGN
+$5.74M
3
SAGE icon
Sage Therapeutics
SAGE
+$5.31M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$5.25M
5
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$4.9M

Sector Composition

Rank Sector Weight
1 Healthcare 86.43%
2 Miscellaneous 13.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
XBI icon
1
State Street SPDR S&P Biotech ETF
XBI
$9.67B
$40.9M 9.31%
431,215
-52,785
-11% -$4.9M
2022 Q1
8 quarters
STXS icon
2
Stereotaxis
STXS
$104M
$35.7M 8.13%
13,680,554
– –
2013 Q2
43 quarters
CYTK icon
3
Cytokinetics
CYTK
$8.78B
$27.9M 6.35%
398,100
-1,900
-0.5% -$147K
2021 Q3
10 quarters
IDYA icon
4
IDEAYA Biosciences
IDYA
$3.25B
$19.6M 4.46%
446,341
-70,000
-14% -$3.01M
2020 Q3
14 quarters
MRUS icon
5
DELISTED
Merus
MRUS
$17.1M 3.89%
378,995
-75,875
-17% -$3.08M
2021 Q1
12 quarters
RVMD icon
6
Revolution Medicines
RVMD
$41.7B
$16.5M 3.76%
511,894
– –
2020 Q4
13 quarters
VKTX icon
7
Viking Therapeutics
VKTX
$3.29B
$15.9M 3.62%
194,117
-54,100
-22% -$2.41M
2018 Q4
21 quarters
SNDX icon
8
Syndax Pharmaceuticals
SNDX
$1.22B
$15.7M 3.57%
659,574
-83,000
-11% -$1.85M
2020 Q2
15 quarters
IBB icon
9
iShares Biotechnology ETF
IBB
$10.4B
$14.1M 3.2%
102,500
– –
2016 Q4
29 quarters
ASND icon
10
Ascendis Pharma A/S
ASND
$14.8B
$14M 3.18%
92,472
-31,000
-25% -$4.42M
2021 Q4
9 quarters
XENE icon
11
Xenon Pharmaceuticals
XENE
$3.26B
$11.8M 2.68%
273,739
-3,000
-1% -$138K
2015 Q3
34 quarters
DAWN icon
12
DELISTED
Day One Biopharmaceuticals
DAWN
$11M 2.51%
666,463
-20,000
-3% -$299K
2023 Q2
3 quarters
BPMC icon
13
DELISTED
Blueprint Medicines
BPMC
$10.1M 2.31%
106,763
-4,100
-4% -$352K
2016 Q4
29 quarters
NBIX icon
14
Neurocrine Biosciences
NBIX
$13.7B
$9.88M 2.25%
71,615
-1,000
-1% -$137K
2016 Q1
32 quarters
KALV icon
15
DELISTED
KalVista Pharmaceuticals
KALV
$9.57M 2.18%
806,973
+205,941
+34% +$2.75M
2021 Q1
12 quarters
TNDM icon
16
Tandem Diabetes Care
TNDM
$1.12B
$9.14M 2.08%
258,208
+37,500
+17% +$1M
2023 Q2
3 quarters
DXCM icon
17
DexCom
DXCM
$31.7B
$9.09M 2.07%
65,552
-2,000
-3% -$251K
2017 Q3
26 quarters
KURA icon
18
Kura Oncology
KURA
$855M
$8.8M 2%
412,663
-80,021
-16% -$1.56M
2017 Q3
26 quarters
ATRC icon
19
AtriCure
ATRC
$2.92B
$8.24M 1.88%
271,029
+145,500
+116% +$4.87M
2013 Q2
43 quarters
MORF icon
20
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$8.16M 1.86%
231,748
– –
2020 Q4
13 quarters
AXGN icon
21
Axogen
AXGN
$2.11B
$7.55M 1.72%
935,894
– –
2021 Q4
9 quarters
BHVN icon
22
Biohaven
BHVN
$1.64B
$6.49M 1.48%
118,730
-50,042
-30% -$2.48M
2022 Q3
6 quarters
TSVT icon
23
DELISTED
2seventy bio
TSVT
$6.44M 1.47%
1,204,051
-243,414
-17% -$1.14M
2023 Q2
3 quarters
EWTX icon
24
Edgewise Therapeutics
EWTX
$4.02B
$5.59M 1.27%
306,197
-143,187
-32% -$2.28M
2022 Q1
8 quarters
ALEC icon
25
Alector
ALEC
$207M
$5.5M 1.25%
912,928
+303,023
+50% +$1.98M
2021 Q3
10 quarters
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, DAFNA Capital Management held 86 positions worth $439M, up 5.3% from $417M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

DAFNA Capital Management withdrew a net $50M in Q1 2024, closing 14 positions and reducing 30 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $15.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier, followed by Miscellaneous.

Against the trend, DAFNA Capital Management opened a new position in Insulet worth $2.73M.

  • DAFNA Capital Management's largest Q1 2024 buy was Insulet: 15,900 shares worth $2.73M.
  • DAFNA Capital Management added most to AtriCure in Q1 2024, an estimated $4.87M increase.
  • DAFNA Capital Management's biggest Q1 2024 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $4.9M.
  • DAFNA Capital Management fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $15.2M.
  • DAFNA Capital Management's ten largest holdings make up 49% of its $439M portfolio in Q1 2024.
  • DAFNA Capital Management opened 10 new positions and closed 14 in Q1 2024.
  • DAFNA Capital Management's portfolio value rose 5.3% quarter-over-quarter to $439M.

Based on DAFNA Capital Management's 13F filing for Q1 2024, filed 15 May 2024.